1. Home
  2. CEG vs VRTX Comparison

CEG vs VRTX Comparison

Compare CEG & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Constellation Energy Corporation

CEG

Constellation Energy Corporation

HOLD

Current Price

$288.13

Market Cap

110.3B

Sector

Utilities

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$469.55

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CEG
VRTX
Founded
1999
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
EDP Services
Sector
Utilities
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
110.3B
115.7B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
CEG
VRTX
Price
$288.13
$469.55
Analyst Decision
Buy
Buy
Analyst Count
13
27
Target Price
$406.92
$506.88
AVG Volume (30 Days)
3.2M
1.3M
Earning Date
02-17-2026
02-12-2026
Dividend Yield
0.54%
N/A
EPS Growth
N/A
N/A
EPS
8.73
14.22
Revenue
$24,841,000,000.00
$11,723,300,000.00
Revenue This Year
$3.87
$10.93
Revenue Next Year
$11.91
$8.44
P/E Ratio
$32.90
$32.86
Revenue Growth
3.58
10.33
52 Week Low
$161.35
$362.50
52 Week High
$412.70
$519.68

Technical Indicators

Market Signals
Indicator
CEG
VRTX
Relative Strength Index (RSI) 30.86 58.90
Support Level $325.80 $429.00
Resistance Level $302.73 $472.58
Average True Range (ATR) 13.94 13.53
MACD -5.91 0.01
Stochastic Oscillator 2.88 69.49

Price Performance

Historical Comparison
CEG
VRTX

About CEG Constellation Energy Corporation

Constellation Energy Corp producer of carbon-free energy and a supplier of energy products and services. The company offers generating capacity that includes nuclear, wind, solar, natural gas, and hydroelectric assets. It sells electricity, natural gas, and other energy-related products and sustainable solutions to various types of customers, including distribution utilities, municipalities, cooperatives, and commercial, industrial, public sector, and residential customers in markets across multiple geographic regions. Its operating segments and reporting units are Mid-Atlantic, Midwest, New York, ERCOT, and Other Power Regions.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: